TP53 and cancer: Loss of p53 activity, by mutation or MDM2 overexpression, is the most common event in cancer development, and, in the last decade, many studies have been conducted to identify small-molecule inhibitors of MDM2−p53 interaction as a therapeutic strategy for cancer treatment [9,10,11].